סלג'ין ואקסלרון הודיעו ש-Luspatercept השיגה את הנקודה הסופית הראשונית ואת כל הנקודות הסופיות המשניות החשובות במחקר BELIEVE שלב 3 במבוגרים עם תלסמיה בטא שתלויה בעירויים

Celgene Corporation ו-Acceleron Pharma Inc. הודיעו היום על תוצאות של מחקר קליני שלב 3, אקראי, עם סמיות כפולה רב-מרכזי (BELIEVE). Luspatercept השיגה שיפור עם מובהקות סטטיסטית גבוהה בנקודה הסופית הראשונית בתגובת כדוריות הדם האדומות, שהוגדרה כהפחתה של לפחות 33 אחוז מקו הבסיס בנטל העירוי של כדוריות אדומות עם הפחתה של לפחות שתי יחידות בתקופה שהוגדרה בפרוטוקול של 12 שבועות עוקבים, משבוע 13 עד שבוע 24, בהשוואה לפלצבו.

BELIEVE העריך את היעילות והבטיחות של luspatercept בתוספת הטיפול התומך הטוב ביותר לעומת פלצבו בתוספת הטיפול התומך הטוב ביותר במבוגרים עם תלסמיה בטא שתלויה בעירויים.

Results showed a significant reduction in transfusion burden compared to placebo

Safety profile generally consistent with previously reported data

Regulatory submissions planned in the United States and Europe in the first half of 2019

SUMMIT, N.J. & CAMBRIDGE, Mass., 9 July 2018, (BUSINESS WIRE):

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 percent reduction from baseline in red blood cell (RBC) transfusion burden with a reduction of at least 2 units during the protocol-defined period of 12 consecutive weeks, from week 13 to week 24, compared to placebo.

BELIEVE evaluated the efficacy and safety of luspatercept plus best supportive care versus placebo plus best supportive care in adults with transfusion-dependent beta-thalassemia.

In addition to achieving the primary endpoint of the study, luspatercept also met all key secondary endpoints of demonstrating statistically significant improvements in RBC transfusion burden from baseline of at least a 33 percent reduction during the period from week 37 to week 48, at least a 50 percent reduction during the period from week 13 to week 24, at least a 50 percent reduction during the period from week 37 to week 48, and a mean change in transfusion burden from week 13 to week 24.

Adverse events observed in the study were generally consistent with previously reported data.

"For decades, the management of beta-thalassemia in adults has been limited to transfusions and iron chelation. Reduction of transfusion burden represents an important step forward for patients with this rare and debilitating blood disease," said Jay Backstrom, M.D., Chief Medical Officer for Celgene. "We thank the patients, as well as their families and physicians, for their participation in the BELIEVE study."

"The BELIEVE study marks the second positive phase III study for luspatercept and underscores the potential of this erythroid maturation agent to impact a range of diseases associated with chronic anemia," said Habib Dable, President and Chief Executive Officer of Acceleron. "We continue to explore luspatercept across our broader development programs, including non-transfusion dependent beta-thalassemia in the ongoing BEYOND study."

The companies also recently announced that luspatercept met the primary and key secondary endpoints in the MEDALIST study, a phase III, randomized, double-blind, multi-center clinical trial evaluating the efficacy and safety of luspatercept versus placebo in patients with IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) with chronic anemia and refractory to, intolerant of, or ineligible for treatment with an erythropoietin-stimulating agent (ESA), ring sideroblast-positive and require frequent RBC transfusions.

Data from BELIEVE and MEDALIST will be submitted to a future medical meeting in 2018. The companies plan to submit regulatory applications for luspatercept in the United States and Europe in the first half of 2019.

Luspatercept is not approved for any indication in any geography.

About Luspatercept

Luspatercept is a first-in-class erythroid maturation agent (EMA) that is believed to regulate late-stage red blood cell maturation. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase III clinical trials continue to evaluate the safety and efficacy of luspatercept in patients with MDS (the MEDALIST trial) and in patients with beta-thalassemia (the BELIEVE trial). A Phase III trial is being planned in first-line, lower-risk, MDS patients (the COMMANDS trial). The BEYOND Phase II trial in non-transfusion-dependent beta-thalassemia and a Phase II trial in myelofibrosis are ongoing. For more information, please visit www.clinicaltrials.gov.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com.

Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Contacts

Celgene Corporation
Investors:
+1-908-673-9628
[email protected]
or
Media:
+1-908-673-2275
[email protected]
or
Acceleron Pharma Inc.
Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
Matt Fearer, 617-301-9557
Director, Corporate Communications

Source: Celgene Corporation

View this news release online at:
http://www.businesswire.com/news/home/20180709005856/en

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית BUSINESS WIRE